Miriam Hernando-Rodriguez

Miriam Hernando-Rodriguez

Auto-generated profile, based on publicly available information

Miriam Hernando-Rodriguez

Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain; Advanced Therapies Mixed Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cytotherapy
Verified
Journal Article
Closed access
JVJaris Valencia
Jaris Valencia
BBBelén Blanco
Belén Blanco
RYRosa Yáñez
Rosa Yáñez
MVMiriam Vázquez
Miriam Vázquez
CSCarmen Herrero Sánchez
Carmen Herrero Sánchez
Agustín G. ZapataAgustín G. Zapata
Agustín G. Zapata

7 September 2015 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MFMaria Fernandez-Garcia
Maria Fernandez-Garcia
RYRosa Yanez
Rosa Yanez
RSRebeca Sánchez-Domínguez
Rebeca Sánchez-Domínguez
MHMiriam Hernando-Rodriguez
Miriam Hernando-Rodriguez
MPMiguel Peces-Barba
Miguel Peces-Barba
MLMaría L. Lamana
María L. Lamana
Introduction: Studies have proposed that mesenchymal stem cells (MSCs) improve the hematopoietic engraftment in allogeneic or xenogeneic transplants and this is probably due to the MSCs’ immunosuppressive properties. Our study aimed to discern, for the first time, whether MSC infusion could facilitate the engraftment of hematopoietic stem cells (HSCs) in autologous transplantations models, where no immune rejection of donor HSCs is expected. Methods: Recipient mice (CD45.2) mice, conditioned with moderate doses of radiation (5-7 Gy), were transplanted with low numbers of HSCs (CD45.1/CD45.2) either as a sole population or co-infused with increasing numbers of adipose-derived-MSCs (Ad-MSCs). The influence of Ad-MSC infusion on the short-term and long-term engraftment of donor HSCs was investigated. Additionally, homing assays and studies related with the administration route and with the Ad-MSC/HSC interaction were conducted. Results: Our data show that the co-infusion of Ad-MSCs with low numbers of purified HSCs significantly improves the short-term and long-term hematopoietic reconstitution of recipients conditioned with moderate irradiation doses. This effect was Ad-MSC dose-dependent and associated with an increased homing of transplanted HSCs in recipients’ bone marrow. In vivo and in vitro experiments also indicate that the Ad-MSC effects observed in this autologous transplant model are not due to paracrine effects but rather are related to Ad-MSC and HSC interactions, allowing us to propose that Ad-MSCs may act as HSC carriers, facilitating the migration and homing of the HSCs to recipient bone marrow niches. Conclusion: Our results demonstrate that Ad-MSCs facilitate the engraftment of purified HSCs in an autologous mouse transplantation model, opening new perspectives in the application of Ad-MSCs in autologous transplants, including HSC gene therapy.

22 January 2013 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LMLorea Manterola
Lorea Manterola
MHM Hernando-Rodríguez
M Hernando-Rodríguez
ARA Ruiz
A Ruiz
AAA Apraiz
A Apraiz
OAO Arrizabalaga
O Arrizabalaga
José ZugazaJosé Zugaza
José Zugaza
1–42 β-Amyloid (Aβ1–42) peptide is a key molecule involved in the development of Alzheimer’s disease. Some of its effects are manifested at the neuronal morphological level. These morphological changes involve loss of neurites due to cytoskeleton alterations. However, the mechanism of Aβ1–42 peptide activation of the neurodegenerative program is still poorly understood. Here, Aβ1–42 peptide-induced transduction of cellular death signals through the phosphatidylinositol 3-kinase (PI3K)/phosphoinositol-dependent kinase (PDK)/novel protein kinase C (nPKC)/Rac 1 axis is described. Furthermore, pharmacological inhibition of PDK1 and nPKC activities blocks Rac 1 activation and neuronal cell death. Our results provide insights into an unsuspected connection between PDK1, nPKCs and Rac 1 in the same signal-transduction pathway and points out nPKCs and Rac 1 as potential therapeutic targets to block the toxic effects of Aβ1–42 peptide in neurons.

28 July 2011 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
MHMiriam Hernando‐Rodriguez
Miriam Hernando‐Rodriguez
NRNatalia Rey‐Barja
Natalia Rey‐Barja
XMXabier Marichalar Mendia
Xabier Marichalar Mendia
MRMaria J. Rodriguez‐Tojo
Maria J. Rodriguez‐Tojo
AAAmelia Acha‐Sagredo
Amelia Acha‐Sagredo
JAJose M. Aguirre‐Urizar
Jose M. Aguirre‐Urizar

1 February 2011
Verified
Journal Article
Closed access
XMXabier Marichalar Mendia
Xabier Marichalar Mendia
AAAmelia Acha-Sagredo
Amelia Acha-Sagredo
MRMaria Jose Rodriguez-Tojo
Maria Jose Rodriguez-Tojo
NRNatalia Rey-Barja
Natalia Rey-Barja
MHMiriam Hernando-Rodriguez
Miriam Hernando-Rodriguez
JAJose Manuel Aguirre-Urizar
Jose Manuel Aguirre-Urizar

8 June 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
AMAlba Maiques-Diaz
Alba Maiques-Diaz
MHMiriam Hernando
Miriam Hernando
ASAmanda Sánchez-López
Amanda Sánchez-López
ARAna Rio-Machin
Ana Rio-Machin
MSMahesh Shrestha
Mahesh Shrestha
SASara Alvarez
Sara Alvarez